Zura Bio Ltd (ZURA) SEC Filings & Earnings Calls

Pre-revenue biotech with increasing R&D spend and net loss; dependent on clinical trial success

“R&D expenses increased 137.9% YoY to $20.7M; net loss widened to $26.3M from $16.0M”

No revenue or approved products

“We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word

Significant operating losses and need for additional capital

“Since our inception, we have incurred significant operating losses. Our net loss for the three and six months ended June 30, 2026 was $26.3 million and $50.5 million, respectively.” · word for word

Clinical trial failure risk

“Our lead product candidate is in the clinical testing stage; however, prior to the initiation of TibuSHIELD and TibuSURE in May 2025 and December 2024, respectively, we had not conducted any clinical trials.” · word for word

Dependence on third-party manufacturers and licensors

“We are obligated to make payments to Lilly, Pfizer, Lonza, and WuXi Biologics under license agreements.”

Pre-revenue company with widening net loss; no approved products; clinical trial risk.

“Net loss increased to $24.2M from $17.4M; no revenue; pipeline still in Phase 2.”

Dilution risk from equity offering; 144M gross proceeds issued in February 2026.

“Completed underwritten public offering of Class A ordinary shares and pre-funded warrants.”

Clinical-stage company with no approved products or revenue

“We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word

Significant accumulated deficit and ongoing losses

“As of March 31, 2026, we had an accumulated deficit of $248.8 million.” · word for word

Dependence on future capital raises

“We will need to raise substantial additional capital in the future.” · word for word

Macroeconomic and geopolitical uncertainties

“Macroeconomic conditions, including uncertainties associated with the changes to and by the United States federal government administration, the ongoing conflicts in Iran and the broader Middle East, the ongoing conflict between Ukraine and Russia, conflicts in Mexico, international trade policies (including tariffs, sanctions, and trade barriers)...” · word for word

Significant dilution from pre-funded warrants

“As of the Record Date, there were 94,880,710 Class A ordinary shares issued and outstanding and pre-funded warrants to acquire 29,295,396 Class A ordinary shares, representing approximately 95.06% of our capitalization on a fully-diluted basis.” · word for word

Related-party transaction risk with Athanor Capital

“the Company paid Athanor an upfront fee in an amount equal to $7.3 million and shall pay a one-time milestone payment in the amount of $25.0 million after the occurrence of the earliest of the following events: (i) the Company or ZB17 undergoes a Change of Control... (ii) the consummation by the Company or ZB17 of a sale of assets resulting in net proceeds i”

Pre-revenue biotech with no approved products; significant losses and need for additional capital.

“Zura Bio has incurred significant losses since inception, and expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability.” · word for word

Clinical trial failure risk

“The Phase 2 clinical trial in moderate-to-severe AD was terminated early following a planned interim analysis due to lack of efficacy.” · word for word

Supply chain / geopolitical risk

“The PRC, and WuXi specifically, have faced increased scrutiny by the U.S. government, which could necessitate the selection of a new manufacturer and require additional stability studies thus impacting our ability to supply torudokimab to meet future demand.”

Dilution from equity offering; pre-revenue biotech with no approved products.

“18.2M shares + 1.8M pre-funded warrants + 3M option shares; net proceeds $134.6M”

Clinical trial failure

“Our clinical trials may not be conducted as planned or completed on schedule, if at all, and a failure of one or more clinical trials can occur at any stage.” · word for word

Tariff cost pressure

“Current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with APIs, raw materials, laboratory equipment and research materials and components.” · word for word

Liquidity risk

“We have incurred significant operating losses... we anticipate that our expenses will increase significantly.”

Regulatory disruption

“Disruptions at the FDA, EMA, the European Commission and other applicable U.S. and foreign government agencies and regulatory authorities caused by funding shortages, furloughs or other concerns could hinder their ability to hire and retain key leadership and other personnel.” · word for word

Clinical trial execution risk; topline data not expected until H2 2026.

“Topline data expected in the second half of 2026 for both Phase 2 trials.”

No approved products or revenue; reliance on cash reserves.

“Clinical-stage company with no products approved for commercial sale.”